Posted by Michael Wonder on 30 Mar 2022
ImmunoGen submits biologics license application to the US Food and Drug Administration for mirvetuximab soravtansine in ovarian cancer
29 March 2022 - Submission based on positive results from pivotal Phase 3 SORAYA trial.
ImmunoGen today announced that it has submitted a biologics license application under the accelerated approval pathway to the U.S. FDA for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.
